Alan Schneyer to Recombinant Proteins
This is a "connection" page, showing publications Alan Schneyer has written about Recombinant Proteins.
Connection Strength
0.333
-
Sidis Y, Mukherjee A, Keutmann H, Delbaere A, Sadatsuki M, Schneyer A. Biological activity of follistatin isoforms and follistatin-like-3 is dependent on differential cell surface binding and specificity for activin, myostatin, and bone morphogenetic proteins. Endocrinology. 2006 Jul; 147(7):3586-97.
Score: 0.054
-
del Re E, Sidis Y, Fabrizio DA, Lin HY, Schneyer A. Reconstitution and analysis of soluble inhibin and activin receptor complexes in a cell-free system. J Biol Chem. 2004 Dec 17; 279(51):53126-35.
Score: 0.049
-
Sidis Y, Tortoriello DV, Holmes WE, Pan Y, Keutmann HT, Schneyer AL. Follistatin-related protein and follistatin differentially neutralize endogenous vs. exogenous activin. Endocrinology. 2002 May; 143(5):1613-24.
Score: 0.041
-
Schneyer AL, Hall HA, Lambert-Messerlian G, Wang QF, Sluss P, Crowley WF. Follistatin-activin complexes in human serum and follicular fluid differ immunologically and biochemically. Endocrinology. 1996 Jan; 137(1):240-7.
Score: 0.026
-
Lambert-Messerlian GM, Crowley WF, Schneyer AL. Extragonadal alpha-inhibin precursor proteins circulate in human male serum. J Clin Endocrinol Metab. 1995 Oct; 80(10):3043-9.
Score: 0.026
-
Schneyer AL, Rzucidlo DA, Sluss PM, Crowley WF. Characterization of unique binding kinetics of follistatin and activin or inhibin in serum. Endocrinology. 1994 Aug; 135(2):667-74.
Score: 0.024
-
Schneyer AL, O'Neil DA, Crowley WF. Activin-binding proteins in human serum and follicular fluid. J Clin Endocrinol Metab. 1992 Jun; 74(6):1320-4.
Score: 0.021
-
Schneyer AL, Sluss PM, Whitcomb RW, Martin KA, Sprengel R, Crowley WF. Precursors of alpha-inhibin modulate follicle-stimulating hormone receptor binding and biological activity. Endocrinology. 1991 Oct; 129(4):1987-99.
Score: 0.020
-
Schneyer AL, Mason AJ, Burton LE, Ziegner JR, Crowley WF. Immunoreactive inhibin alpha-subunit in human serum: implications for radioimmunoassay. J Clin Endocrinol Metab. 1990 Apr; 70(4):1208-12.
Score: 0.018
-
Sidis Y, Schneyer AL, Keutmann HT. Heparin and activin-binding determinants in follistatin and FSTL3. Endocrinology. 2005 Jan; 146(1):130-6.
Score: 0.012
-
Keutmann HT, Schneyer AL, Sidis Y. The role of follistatin domains in follistatin biological action. Mol Endocrinol. 2004 Jan; 18(1):228-40.
Score: 0.011
-
Sidis Y, Schneyer AL, Sluss PM, Johnson LN, Keutmann HT. Follistatin: essential role for the N-terminal domain in activin binding and neutralization. J Biol Chem. 2001 May 25; 276(21):17718-26.
Score: 0.009
-
McConnell DS, Wang Q, Sluss PM, Bolf N, Khoury RH, Schneyer AL, Midgley AR, Reame NE, Crowley WF, Padmanabhan V. A two-site chemiluminescent assay for activin-free follistatin reveals that most follistatin circulating in men and normal cycling women is in an activin-bound state. J Clin Endocrinol Metab. 1998 Mar; 83(3):851-8.
Score: 0.008
-
Besecke LM, Guendner MJ, Schneyer AL, Bauer-Dantoin AC, Jameson JL, Weiss J. Gonadotropin-releasing hormone regulates follicle-stimulating hormone-beta gene expression through an activin/follistatin autocrine or paracrine loop. Endocrinology. 1996 Sep; 137(9):3667-73.
Score: 0.007
-
Wang QF, Khoury RH, Smith PC, McConnell DS, Padmanahban V, Midgley AR, Schneyer AL, Crowley WF, Sluss PM. A two-site monoclonal antibody immunoradiometric assay for human follistatin: secretion by a human ovarian teratocarcinoma-derived cell line (PA-1). J Clin Endocrinol Metab. 1996 Apr; 81(4):1434-41.
Score: 0.007